Prevalence and clinical significance of IgG isotype anti-β2-glycoprotein I antibodies in antiphospholipid syndrome: A comparative study w

Sanmarco, Marielle; Soler, Christophe; Christides, C.; Raoult, Didier; Weiller, Pierre Jean; Gérolami, V.; Bernard, Dominique

doi:10.1016/s0022-2143(97)90004-4

Cited by 62 publications

(38 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Detection of Abs with defined specificity for ␤2GPI may be more specific (7)(8)(9), but anti-␤2GPI assays lack standardization and are not currently used in routine patient care.…”

Section: P Atients With the Antiphospholipid (Apl)mentioning

confidence: 99%

Monocyte Tissue Factor Induction by Activation of β2-Glycoprotein-I-Specific T Lymphocytes Is Associated with Thrombosis and Fetal Loss in Patients with Antiphospholipid Antibodies

Visvanathan¹,

Geczy

Harmer

et al. 2000

The Journal of Immunology

View full text Add to dashboard Cite

Antiphospholipid (aPL) syndrome (APS) is characterized by thromboembolic events, thrombocytopenia, or recurrent miscarriage associated with aPL Abs with specificity for β2-glycoprotein-I (β2GPI). We recently reported that at least 44% of patients with the APS possess circulating type 1 (Th1) CD4+ T cells that proliferate and secrete IFN-γ when stimulated with β2GPI in vitro. In this study, we show that stimulation of PBMCs from 20 APS patients with β2GPI induced substantial monocyte tissue factor (TF) (80 ± 11 TF stimulation index (TF-SI)), whereas no induction was observed using PBMCs from 13 patients with aPL Abs without APS (6 ± 1 TF-SI) or 7 normal and 7 autoimmune controls (5 ± 1 and 3 ± 1 TF-SI, respectively) (p < 0.0001). TF induction on monocytes by β2GPI was dose dependent and required CD4+ T lymphocytes and class II MHC molecules. Because monocyte TF induction by β2GPI was observed in all patients with APS, but not in any patient with aPL Abs without APS, this response is a potentially useful predictor for APS in patients with aPL Abs, as well as providing mechanistic insight into thrombosis and fetal loss in these patients.

show abstract

“…Detection of Abs with defined specificity for ␤2GPI may be more specific (7)(8)(9), but anti-␤2GPI assays lack standardization and are not currently used in routine patient care.…”

Section: P Atients With the Antiphospholipid (Apl)mentioning

confidence: 99%

Monocyte Tissue Factor Induction by Activation of β2-Glycoprotein-I-Specific T Lymphocytes Is Associated with Thrombosis and Fetal Loss in Patients with Antiphospholipid Antibodies

Visvanathan¹,

Geczy

Harmer

et al. 2000

The Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…In studies where irradiated plates were used (this study and Guerrin et al, 12 Sanmarco and colleagues 18 ) the overall sensitivity (0.58; 95% CI, 0.54 to 0.62) and specificity (0.95; 95% CI, 0.94 to 0.97) were higher than for studies where non-irradiated plates were used 3 19 (sensitivity, 0.35; 955 CI, 0.30 to 0.40; specificity, 0.78; 95% CI, 0.73 to 0.82). Direct comparisons between the use of irradiated and non-irradiated plates may not be valid because of the diVerent case mix composition of the studies.…”

Section: Figure 1 Receiver Operating Characteristic Curves For Anticamentioning

confidence: 78%

Optimising testing for phospholipid antibodies

Helbert¹,

Bodger²,

Cavenagh³

et al. 2001

Journal of Clinical Pathology

View full text Add to dashboard Cite

Aim-To compare anticardiolipin (ACL) and anti-2 glycoprotein 1 ( 2gp1) enzyme linked immunosorbent assays (ELISAs) in the diagnosis of antiphospholipid syndrome (APS) and to incorporate these results into a meta-analysis of published data. Method-Three representative commercial ACL ELISAs and an in house 2gp1 assay were optimised and then assessed on 124 sera from normal donors, patients with infection, or patients with APS. A Medline search was screened for papers meeting defined criteria to conduct a meta-analysis. The performance of the assays used in this study was included. Results-A non-quantitative ACL assay performed at least as well as the anti2gp1 assay in the diagnosis of APS. Meta-analysis confirmed that neither assay is perfect, although the anti-2gp1 assay had a higher specificity and lower sensitivity than the ACL assay. Conclusions-The pooled data suggest that the ACL assay is used to investigate thrombosis without overt underlying pathology and that the improved specificity of the anti-2gp1 assay is exploited where infection, connective tissue disease, or atheroma are present. (J Clin Pathol 2001;54:693-698)

show abstract

“…25,27,29,31,[35][36][37][38][39][40][41][42][43][44][46][47][48][49][50][51] Overall, 20 associations reached statistical significance in the case of anti-␤2-glycoprotein I antibodies, and 16 were significant for anticardiolipin antibodies (Table 3). Analysis in relation to the type of thrombosis showed that anticardiolipin antibodies seemd more often associated with arterial events, and anti-␤2-glycoprotein I antibodies with venous thrombosis.…”

Section: Comparison Of Anti-␤2-glycoprotein I and Anticardiolipin Antmentioning

confidence: 99%

Anti–β2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome

Galli

Luciani

Bertolini

et al. 2003

Blood

405

260

View full text Add to dashboard Cite

Prevalence and clinical significance of IgG isotype anti-β2-glycoprotein I antibodies in antiphospholipid syndrome: A comparative study w

Cited by 62 publications

References 24 publications

Monocyte Tissue Factor Induction by Activation of β2-Glycoprotein-I-Specific T Lymphocytes Is Associated with Thrombosis and Fetal Loss in Patients with Antiphospholipid Antibodies

Monocyte Tissue Factor Induction by Activation of β2-Glycoprotein-I-Specific T Lymphocytes Is Associated with Thrombosis and Fetal Loss in Patients with Antiphospholipid Antibodies

Optimising testing for phospholipid antibodies

Anti–β2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome

Contact Info

Product

Resources

About